OneSource Specialty Pharma LimitedNSE: ONESOURCE

Onesource Specialty Pharma Limited Press Release Apr 21 2026

· Issued by OneSource Specialty Pharma Limited via NSE India

Filed with NSE · · 3 pages · English

Summary by 6ix AI

OneSource Specialty Pharma Limited has issued a press release regarding a significant development in collaboration with Orbicular Pharmaceutical Technologies. The release announces that Orbicular has secured tentative U.S. FDA approval for a generic version of Ozempic, with OneSource acting as the contract development and manufacturing organization partner. This achievement underscores the integrated development model between Orbicular and OneSource, highlighting their capabilities in manufacturing and regulatory compliance. The press release emphasizes OneSource's commitment to strengthening its position as a global CDMO partner for complex pharmaceutical products.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Onesource Specialty Pharma Limited has informed the Exchange regarding a press release dated April 21, 2026, titled "Orbicular s Partner secures tentative U.S. ANDA approval for a generic version of Ozempic® (Semaglutide Injection), supported by OneSource as CDMO partner".

OneSource Specialty Pharma Limited on 6ix

Earlier from OneSource Specialty Pharma

Later from OneSource Specialty Pharma

All OneSource Specialty Pharma news releases